M.D., Duke University, 1984
Behavioral Pharmacology (BPRU)
Department of Psychiatry 3rd Floor
5510 Nathan Shock Drive
Baltimore, MD 21224 umccann@jhmi.edu
(410) 550-1972
(410) 550-0030 1980 Summa Cum Laude, Princeton University
1976-1980 Four-Year Academic Scholarship, Princeton University
1980 Phi Beta Kappa and Sigma Xi Societies
1980 Sigma Xi Award in Psychology, Princeton University
1980 Howard Hughes Foundation Student Scholar, Peter Bent Brigham Hospital
1987-1988 Moos Fellowship for Clinical Research, Stanford University McCann UD, Agras WS. Successful treatment of non-purging bulimia with desipramine: A double blind placebo controlled study. American Journal of Psychiatry 1990;147(11):1509-1513. McCann UD, Penetar DM, Belenky GL. Acute dystonic reaction in normal humans caused by catecholamine depletion. Clin Neuropharmacology 1990;13(6):565-568. McCann UD, Penetar DM, Belenky GL. Panic attacks in healthy volunteers following a-methyl-para-tyrosine administration. Biological Psychiatry 1991;30:413-416. McCann UD, Ricaurte GA. Lasting neuropsychiatric sequelae of (+) methylenedioxymethamphetamine (“Ecstasy”). Journal of Clinical Psychopharmacology 1991;11:302-306. McCann UD, Rossiter EM, King R, Agras WS. Non-purging bulimia: A distinct subtype of bulimia nervosa. International Journal of Eating Disorders 1991:10(6):679-687. McCann UD, Penetar DL, Shaham Y, Thorne D, Gillin JC, Sing H, Thomas H, Belenky G. Sleep deprivation and impaired cognition: the role of catecholamines. Biological Psychiatry 1992;31(11):1082-1097. Ricaurte GA, McCann UD. Neurotoxic amphetamine analogs: effects in Monkeys and implications for humans.Annals of the New York Academy of Science 1992;648:371-382. McCann UD, Penetar DL, Shaham et al: Mood effects of catecholamine depletion in rested and sleep deprived normal volunteer. Neuropsychopharmacology 1993;8(4):345-356. McCann UD, Ricaurte GA. Subjective and neurotoxic effects of (±) 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are separable: clinical evidence. Journal of Clinical Psychopharmacology 1993;13:214-217. McCann UD, Ridenour A, Shaham Y, Ricaurte GA. Brain serotonergic neurotoxicity after MDMA ("Ecstasy"): A controlled study in humans. Neuropsychopharmacology, 1994; 10: 129-138. McCann UD, Ricaurte GA. Use and abuse of ring-substituted amphetamines. In: Amphetamine and its Analogs: Neuropsychopharmacology, Toxicology & Abuse, Cho A and Segal D (eds), Academic Press, NY, 1994;371-381. McCann UD, Thorne D, Hall T, Sing H, Thomas H, Belenky G. The effects of L-DOPA on alertness and mood in AMPT-treated normal volunteers: Further evidence for the role of catecholamines in arousal and anxiety. Neuropsychopharmacology, 1995; 13(1):42-52. McCann UD, Ricaurte GA. On the neurotoxicity of MDMA and related amphetamine derivatives. J Clinical Psychopharmacology 1995;15:295-296. McCann UD, Morgan CM, Geraci M, Murphy D, Post RM. Effects of the 5HT-3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia. Neuropsychopharmacology 1997;17(6):360-369. McCann UD, Ricaurte GA. Aproximacion a la neurobiologia Y neurotoxicidad comparada inducida por la MDMA. In: Extasis (MDMA): Un abordaje comprehensivo (J Bobes Garcia, P Lorenzo Fernandez, PA Saiz Martinez, eds). Psiquiatria Medica, Masson, SA, Madrid 1998; 89-97. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from PET studies with [11C]WIN-35,428. J Neuroscience 1998;18(20):8417-8422. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 1998;352:1433-1437. McCann UD, Mertl M, Eligulashvili V, Ricaurte GA. Cognitive performance in (+) 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") users: a controlled study. Psychopharmacology (Berl). 1999;143(4):417-425. Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with MDMA 7 years previously: factors influencing abnormal recovery. J Neuroscience 1999;19(12):5096-5107. McCann UD, Eligulashvili V, Mertl M, Murphy DL, Ricaurte GA. Altered neuroendocrine and behavioral responses to m-CPP in MDMA users. Psychopharmacology 1999;147:56-65. McCann UD, Eligulashvili V, Ricaurte GA. (+) 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy")-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 2000;42(1):11-16. Ricaurte GA, Yuan J, McCann UD. (+) 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy")-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 2000;42(1):5-10. McCann UD, Ricaurte GA. Experimental studies on MDMA and its potential to damage brain serotonin neurons. Neurotoxicity Research 2001;3(1):85-99. Ricaurte GA and McCann UD: (Invited Editorial) On the long-term effects of MDMA (“Ecstasy”) in humans Lancet. 2001;358(9296):1831-2. McCann UD, Ricaurte GA, Molliver ME. (Invited commentary) MDMA ("Ecstasy") and serotonin neurotoxicity: New findings raise more questions. Archives of General Psychiatry 2001;58(10):907-908. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("Ecstasy"). Science 297, 2260, 2002. Geraci M, Anderson TS, Slate-Cothren S, Post RM, McCann UD. Pentagastrin-induced sleep panic attacks: Panic in the absence of elevated baseline arousal. Biological Psychiatry, 2002;52(12):1183-9. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann, UD. MDMA (“Ecstasy”) and Neurotoxicity. Science June 6 2003; 1503. | 
